Low-grade serous carcinomas of the ovary contain very few point mutations

Research output: Contribution to journalArticle

Abstract

It has been well established that ovarian low-grade and high-grade serous carcinomas are fundamentally different types of tumours. While the molecular genetic features of ovarian high-grade serous carcinomas are now well known, the pathogenesis of low-grade serous carcinomas, apart from the recognition of frequent somatic mutations involving KRAS and BRAF, is largely unknown. In order to comprehensively analyse somatic mutations in low-grade serous carcinomas, we applied exome sequencing to the DNA of eight samples of affinity-purified, low-grade, serous carcinomas. A remarkably small number of mutations were identified in seven of these tumours: a total of 70 somatic mutations in 64 genes. The eighth case displayed mixed serous and endometrioid features and a mutator phenotype with 783 somatic mutations, including a nonsense mutation in the mismatch repair gene, MSH2. We validated representative mutations in an additional nine low-grade serous carcinomas and 10 serous borderline tumours, the precursors of ovarian low-grade, serous carcinomas. Overall, the genes showing the most frequent mutations were BRAF and KRAS, occurring in 10 (38%) and 5 (19%) of 27 low-grade tumours, respectively. Except for a single case with a PIK3CA mutation, other mutations identified in the discovery set were not detected in the validation set of specimens. Our mutational analysis demonstrates that point mutations are much less common in low-grade serous tumours of the ovary than in other adult tumours, a finding with interesting scientific and clinical implications.

Original languageEnglish (US)
Pages (from-to)413-420
Number of pages8
JournalJournal of Pathology
Volume226
Issue number3
DOIs
StatePublished - Feb 2012

Fingerprint

Point Mutation
Ovary
Carcinoma
Mutation
Neoplasms
Genes
Exome
DNA Mismatch Repair
Nonsense Codon
DNA Sequence Analysis
Molecular Biology
Phenotype

Keywords

  • BRAF
  • exome sequencing
  • KRAS
  • ovarian cancer
  • somatic mutations

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

@article{9f5df194a66f4e85bd94b0992ab69792,
title = "Low-grade serous carcinomas of the ovary contain very few point mutations",
abstract = "It has been well established that ovarian low-grade and high-grade serous carcinomas are fundamentally different types of tumours. While the molecular genetic features of ovarian high-grade serous carcinomas are now well known, the pathogenesis of low-grade serous carcinomas, apart from the recognition of frequent somatic mutations involving KRAS and BRAF, is largely unknown. In order to comprehensively analyse somatic mutations in low-grade serous carcinomas, we applied exome sequencing to the DNA of eight samples of affinity-purified, low-grade, serous carcinomas. A remarkably small number of mutations were identified in seven of these tumours: a total of 70 somatic mutations in 64 genes. The eighth case displayed mixed serous and endometrioid features and a mutator phenotype with 783 somatic mutations, including a nonsense mutation in the mismatch repair gene, MSH2. We validated representative mutations in an additional nine low-grade serous carcinomas and 10 serous borderline tumours, the precursors of ovarian low-grade, serous carcinomas. Overall, the genes showing the most frequent mutations were BRAF and KRAS, occurring in 10 (38{\%}) and 5 (19{\%}) of 27 low-grade tumours, respectively. Except for a single case with a PIK3CA mutation, other mutations identified in the discovery set were not detected in the validation set of specimens. Our mutational analysis demonstrates that point mutations are much less common in low-grade serous tumours of the ovary than in other adult tumours, a finding with interesting scientific and clinical implications.",
keywords = "BRAF, exome sequencing, KRAS, ovarian cancer, somatic mutations",
author = "Si{\^a}n Jones and Tian-Li Wang and Kurman, {Robert J} and Kentaro Nakayama and Velculescu, {Victor E} and Bert Vogelstein and Kinzler, {Kenneth W} and Nickolas Papadopoulos and Shih, {Ie Ming}",
year = "2012",
month = "2",
doi = "10.1002/path.3967",
language = "English (US)",
volume = "226",
pages = "413--420",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Low-grade serous carcinomas of the ovary contain very few point mutations

AU - Jones, Siân

AU - Wang, Tian-Li

AU - Kurman, Robert J

AU - Nakayama, Kentaro

AU - Velculescu, Victor E

AU - Vogelstein, Bert

AU - Kinzler, Kenneth W

AU - Papadopoulos, Nickolas

AU - Shih, Ie Ming

PY - 2012/2

Y1 - 2012/2

N2 - It has been well established that ovarian low-grade and high-grade serous carcinomas are fundamentally different types of tumours. While the molecular genetic features of ovarian high-grade serous carcinomas are now well known, the pathogenesis of low-grade serous carcinomas, apart from the recognition of frequent somatic mutations involving KRAS and BRAF, is largely unknown. In order to comprehensively analyse somatic mutations in low-grade serous carcinomas, we applied exome sequencing to the DNA of eight samples of affinity-purified, low-grade, serous carcinomas. A remarkably small number of mutations were identified in seven of these tumours: a total of 70 somatic mutations in 64 genes. The eighth case displayed mixed serous and endometrioid features and a mutator phenotype with 783 somatic mutations, including a nonsense mutation in the mismatch repair gene, MSH2. We validated representative mutations in an additional nine low-grade serous carcinomas and 10 serous borderline tumours, the precursors of ovarian low-grade, serous carcinomas. Overall, the genes showing the most frequent mutations were BRAF and KRAS, occurring in 10 (38%) and 5 (19%) of 27 low-grade tumours, respectively. Except for a single case with a PIK3CA mutation, other mutations identified in the discovery set were not detected in the validation set of specimens. Our mutational analysis demonstrates that point mutations are much less common in low-grade serous tumours of the ovary than in other adult tumours, a finding with interesting scientific and clinical implications.

AB - It has been well established that ovarian low-grade and high-grade serous carcinomas are fundamentally different types of tumours. While the molecular genetic features of ovarian high-grade serous carcinomas are now well known, the pathogenesis of low-grade serous carcinomas, apart from the recognition of frequent somatic mutations involving KRAS and BRAF, is largely unknown. In order to comprehensively analyse somatic mutations in low-grade serous carcinomas, we applied exome sequencing to the DNA of eight samples of affinity-purified, low-grade, serous carcinomas. A remarkably small number of mutations were identified in seven of these tumours: a total of 70 somatic mutations in 64 genes. The eighth case displayed mixed serous and endometrioid features and a mutator phenotype with 783 somatic mutations, including a nonsense mutation in the mismatch repair gene, MSH2. We validated representative mutations in an additional nine low-grade serous carcinomas and 10 serous borderline tumours, the precursors of ovarian low-grade, serous carcinomas. Overall, the genes showing the most frequent mutations were BRAF and KRAS, occurring in 10 (38%) and 5 (19%) of 27 low-grade tumours, respectively. Except for a single case with a PIK3CA mutation, other mutations identified in the discovery set were not detected in the validation set of specimens. Our mutational analysis demonstrates that point mutations are much less common in low-grade serous tumours of the ovary than in other adult tumours, a finding with interesting scientific and clinical implications.

KW - BRAF

KW - exome sequencing

KW - KRAS

KW - ovarian cancer

KW - somatic mutations

UR - http://www.scopus.com/inward/record.url?scp=84855803281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855803281&partnerID=8YFLogxK

U2 - 10.1002/path.3967

DO - 10.1002/path.3967

M3 - Article

VL - 226

SP - 413

EP - 420

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 3

ER -